Stay updated on Dabrafenib, Trametinib, Spartalizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Dabrafenib, Trametinib, Spartalizumab in Melanoma Clinical Trial page.

Latest updates to the Dabrafenib, Trametinib, Spartalizumab in Melanoma Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe history shows a new site revision label v3.3.2 added, with the previous v3.3.1 label removed.SummaryDifference0.1%

- Check21 days agoChange DetectedA new revision entry v3.3.1 appears in the history, replacing the previous v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check29 days agoChange DetectedRemoved the notice about lapse in government funding and operating status from the page. The study record history content remains unchanged.SummaryDifference0.7%

- Check43 days agoChange DetectedThe Record History shows multiple version updates (Study Status, Recruitment Status, and Outcome Measures) across 2020-2024, reflecting administrative changes to the trial record. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check72 days agoChange DetectedCore content updated with a government funding notice and updated operating-status guidance; version updated from v3.1.0 to v3.2.0.SummaryDifference12%

- Check79 days agoChange DetectedUpdated version from v3.0.2 to v3.1.0, indicating a new release.SummaryDifference0.3%

Stay in the know with updates to Dabrafenib, Trametinib, Spartalizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dabrafenib, Trametinib, Spartalizumab in Melanoma Clinical Trial page.